Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

“upfront use of blinatumomab in adolescents and adults with Philadelphia Chromosome–Negative B-cell acute lymphoblastic leukemia: A systematic review and proportional meta-analysis”

View Full Paper
Ask AI
Bookmark
Share

Authors

HFHenri FeroFGFrenki GjikaEFEster Faccin

Discussion

Loading...

Member takes

Overview

Systematic review shows blinatumomab improves remission in adolescents and adults with Ph- B-ALL, indicating enhanced therapy strategies.

Key Points

  • Evaluate the efficacy of blinatumomab-based regimens in treating adolescents and adults with Ph– B-ALL.
  • Systematic search of PubMed, Embase, and Cochrane databases.
  • Included studies with newly diagnosed Ph– B-ALL patients using blinatumomab in induction or consolidation phases.
  • Conducted random-effects meta-analyses for primary outcomes including complete remission and measurable residual disease.
  • 78% complete remission rate post-induction with blinatumomab.
  • 90% MRD negativity in induction-only group; 88% in consolidation group; 89% in both phases.
  • 83% overall survival rate in consolidation subgroup; 52% in both phases, highlighting treatment variation.

Cite This Study

Fero et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1f4https://doi.org/10.1182/blood-2025-6872
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of consolidation-Phase blinatumomab in newly diagnosed B-cell acute lymphoblastic leukemia : A systematic review and meta-analysis2025
  2. 2Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival2025
  3. 3Blinatumomab vs. chemotherapy in pediatrics B-cell ALL: A meta-analysis of randomized controlled trials2025
  4. 4T-cell engaging bispecific antibody shows potent MRD negativity with variable remission and survival outcomes: A bayesian meta-analysis of randomized controlled trials2025
  5. 5Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity2025